This week's Fierce Biotech is brought to you by Lonza Biologics and Integral Molecular.
In this webinar, we explore the challenges of comprehensively assessing the specificity profile when moving a candidate to first-in-human (FIH) studies, through the application of membrane proteome arrays and cell-based immunotoxicity assays. Case studies will highlight how these in vitro assessments add significant value by predicting risk early and how potential clinical safety issues could have been averted by such a comprehensive approach.
|
| You are currently subscribed as newsletter@newslettercollector.com |
